VolitionRx Partners with Hologic to Expand Access to Epigenetic Testing Services

VolitionRx Ltd. has entered into a co-marketing and services agreement with Hologic Diagenode, part of Hologic Inc., to promote Volition's Nu.Q Discover service to pharmaceutical and biotechnology companies. The partnership represents a strategic move to expand market reach for epigenetic testing services that help drug developers accelerate research across multiple disease areas.

The Nu.Q Discover program offers drug developers and scientists a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies. This collaboration could significantly impact how pharmaceutical companies approach drug development by providing enhanced epigenetic analysis capabilities. According to Volition executives, the program has an estimated total addressable market of $200 million annually, indicating substantial commercial potential for both companies.

Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, described the agreement as a significant milestone for the Nu.Q Discover program that will greatly expand customer access to their proprietary assays. We look forward to working with the Hologic team as we strengthen our position in the pharmaco-epigenetics market, to help us to grow our revenues, Kway stated in the announcement available at https://ibn.fm/Spd1c.

Raphael Werding, Head of Life Sciences at Hologic, emphasized the broader applications of nucleosome quantification technology beyond oncology. At Hologic, we have extensive experience not only in oncology but also in other disease areas such as cardiovascular, neurodegenerative, immunology and others; disease areas where we believe nucleosome quantification can provide additional valuable biological insights to our biotech, pharma and academic clients, Werding commented.

The agreement initially covers a one-year term with potential expansion into an exclusive provider arrangement subject to further terms. This partnership comes at a time when epigenetic research is gaining increased attention in pharmaceutical development, as understanding epigenetic modifications can provide crucial insights into disease mechanisms and treatment responses.

For the broader pharmaceutical and biotechnology industries, this collaboration could accelerate drug discovery timelines by providing more comprehensive epigenetic profiling services. The integration of Hologic's established customer relationships with Volition's specialized epigenetic technology creates a powerful combination that may benefit researchers working across multiple therapeutic areas.

The partnership also highlights the growing importance of epigenetics in modern drug development, where understanding how environmental factors and lifestyle choices affect gene expression has become increasingly valuable. As more pharmaceutical companies recognize the importance of epigenetic markers in disease progression and treatment response, services like Nu.Q Discover could become essential tools in the drug development toolkit.